Polymorphisms of CYP2C8 , CYP2C9 and CYP2C19 and risk of coronary heart disease in Russian population

Polonikov, Alexey; Харченко, А. В.; Bykanova, Marina; Sirotina, Svetlana; Ponomarenko, Irina; Бочарова, А. В.; Vagaytseva, Kseniya; Степанов, В. Г.; Бушуева, О. Ю.; Churnosov, Mikhail; Solodilova, Maria

doi:10.1016/j.gene.2017.07.004

Cited by 35 publications

(28 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Polonikov и соавт. изучили возможную роль редких полиморфизмов CYP2C9 rs9332242 и CYP2C9 rs4918758 в развитии предрасположенности к ишемической болезни сердца (ИБС) [24] и эссенциальной гипертензии [25], однако результат был отрицательный.…”

Section: Cyp2c9unclassified

“…Результаты работ по редким аллелям гена CYP2C9 [24,25], а также генам VKORC1 [11,14,20] и GGCX [14] представлены в табл. 1.…”

Section: Cyp2c9unclassified

“…В клинической практике ФГТ гена CYP2C19 применяется для снижения НПР у больных с сердечно-сосудистыми заболеваниями. Фермент цитохрома CYP2C19 участвует в метаболизме сразу нескольких важных классов лекарственных препаратов: бензодиа- Moscow / Москва *¹ [36] Moscow / Москва *² [37] Moscow / Москва *³ [37] Tomsk / Томск * 4 [38] Kursk / Курск* [24] Kursk / Курск* [25] Chelyabinsk / Челябинск * 5 [10] Kursk / Курск* 6 [24] Kursk / Курск* 7 [25] Nanais / Нанайцы [23] Yakuts / Якуты [15] Buryats / Буряты [15] Circassians / Черкесы [21] Yakuts / Якуты [20] Yakuts / Якуты 8 [40] Altaians / Алтайцы [15] Russians / Русские 9 [41] Tuvans / Тувинцы [15] Laks / Лакцы [22] Karachays / Карачаевцы [21] Russians / Русские [16] Avars / Аварцы [22] Russians / Русские [15] Russians / Русские [18] Tatars / Татары [42] Russians / Русские 10 [41] Russians / Русские [17] Russians / Русские 11 [41] Russians / Русские 12 [40] Russians / Русские 13 [41] Dargins / Даргинцы [22] Population / Популяция Prevalence / Распространенность (%)…”

Section: Cyp2c19unclassified

“…установили связь между CYP2C19 rs4244285 GG и повышенным риском развития эссенциальной гипертензии (относительный риск 3,34; 95% доверительный интервал 1,48-7,51; p=0,004) [25]. Те же авторы попытались оценить связь между полиморфизмами гена CYP2C19 и риском развития ИБС в российской популяции, но результаты оказались отрицательными [24].…”

Section: 34unclassified

“…A. Polonikov и соавт. изучили эти полиморфизмы в свете риска развития ИБС в российской популяции [24] и установили их связь с риском развития эссенциальной артериальной гипертензии [25].…”

Section: Cyp2c8unclassified

See 4 more Smart Citations

Multi-Ethnic Analysis of Cardiac Pharmacogenetic Markers of Cytochrome P450 and Membrane Transporters Genes in the Russian Population

Мирзаев

Fedorinov

Ivashchenko

et al. 2019

Racionalʹnaâ farmakoterapiâ v kardiologii

View full text Add to dashboard Cite

Aim. To summarize Russian studies using pharmacogenetic testing as applied to cardiology.Material and methods. The authors conducted an online search for articles in December 2018 using the following databases: PubMed, Google Scholar, eLIBRARY. The search was carried out by keywords: "Russia", "Russian", "cardiology" together with the terms associated with the polymorphic marker, including: «P450», «CYP2C19», «CYP2D6», «CYP2B1», «CYP2B6», «CYP2Е1», «CYP2C8», «CYP2C9», «CYP3A4», «CYP3A5», «CYP1A1», «CYP1A2», «CYP4F2», «CYP4F1», «ABCB1», «SLCO1B1», «VKORC1», «GGCX», «SULT1A1», «CULT1», «CES1», «gene», «genes», «pharmacogenetics», «pharmacogenomics», «ethnic group».Results. Generalization of information allowed to identify obscure genes that need to be investigated in pharmacogenetic studies. This information can be used for the development of dosing algorithms and the priority choice of drugs, considering the results of pharmacogenetic testing and planning future research.Conclusion. The results of the literature review indicate the importance of studying the most clinically valid and clinically useful pharmacogenetic markers (CYP2C19, CYP2C9, VKORC1, SLCO1B1) among various ethnic groups in the Russian Federation. With the accumulation of evidence of clinical validity and clinical utility of other pharmacogenetic markers (CES1, CYP2D6*4, etc.), the problem of interethnic differences in the carriage of clinically significant polymorphisms of these genes identified in previous studies in the Russian Federation increasingly requires attention. The most promising for the introduction into the clinical practice in the Russian Federation in the near future are polymorphic markers of the CYP2C19, CYP2C9, VKORC1 and SLCO1B1 genes.

show abstract

Section: Cyp2c9unclassified

“…Результаты работ по редким аллелям гена CYP2C9 [24,25], а также генам VKORC1 [11,14,20] и GGCX [14] представлены в табл. 1.…”

Section: Cyp2c9unclassified

Section: Cyp2c19unclassified

Section: 34unclassified

Section: Cyp2c8unclassified

See 3 more Smart Citations

Multi-Ethnic Analysis of Cardiac Pharmacogenetic Markers of Cytochrome P450 and Membrane Transporters Genes in the Russian Population

Мирзаев

Fedorinov

Ivashchenko

et al. 2019

Racionalʹnaâ farmakoterapiâ v kardiologii

View full text Add to dashboard Cite

show abstract

Utilizing Large Electronic Medical Record Data Sets to Identify Novel Drug–Gene Interactions for Commonly Used Drugs

Malki

Dawed

Haywood

et al. 2021

Clin Pharma and Therapeutics

View full text Add to dashboard Cite

Real-world prescribing of drugs differs from the experimental systems, physiologicalpharmacokinetic (PK) models and clinical trials used in drug development and licensing, with drugs often used in patients with multiple comorbidities with resultant polypharmacy. The increasing availability of large biobanks linked to electronic healthcare records enables the potential to identify novel drug-gene interactions in large populations of patients. In this study we used 3 Scottish cohorts and UK Biobank to identify drug-gene interactions for the 50 most commonly used drugs and 162 variants in genes involved in drug pharmacokinetics. We defined two phenotypes based upon prescribing behaviour -drug-stop or dose-decrease. Using this approach, we replicate 11 known drug-gene interactions including, for example, CYP2C9/CYP2C8 variants and sulphonylurea/thiazolidinedione prescribing and ABCB1/ABCG2 variants and statin prescribing. We identify 8 novel associations after bonferroni correction, 3 of which are replicated or validated in the UK biobank or have other supporting results: The C-allele at rs4918758 in CYP2C9 was associated with a 25% (15-44%) lower odds of dose reduction of quinine, p=1.6×10 -5 ; the A-allele at rs9895420 in ABCC3 was associated with a 46% (24-62%) reduction in odds of dose reduction with doxazosin, p=1.2×10 -4 , and altered blood pressure response in the UK Biobank; the CYP2D6*2 variant was associated with a 30% (18 %-40%) reduction in odds of stopping ramipril treatment, p=1.01×10 -5 , with similar results seen for enalapril and lisinopril and with other CYP2D6 variants. This study highlights the scope of using large population bioresources linked to medical record data to explore drug-gene interactions at scale.

show abstract

A genome-wide association study of 24-hour urinary excretion of endocrine disrupting chemicals

Lu,

van der Meer,

Kamali

et al. 2024

Environment International

View full text Add to dashboard Cite

Polymorphisms of CYP2C8 , CYP2C9 and CYP2C19 and risk of coronary heart disease in Russian population

Cited by 35 publications

References 54 publications

Multi-Ethnic Analysis of Cardiac Pharmacogenetic Markers of Cytochrome P450 and Membrane Transporters Genes in the Russian Population

Multi-Ethnic Analysis of Cardiac Pharmacogenetic Markers of Cytochrome P450 and Membrane Transporters Genes in the Russian Population

Utilizing Large Electronic Medical Record Data Sets to Identify Novel Drug–Gene Interactions for Commonly Used Drugs

A genome-wide association study of 24-hour urinary excretion of endocrine disrupting chemicals

Contact Info

Product

Resources

About